EO 14398 BAA targeted polymer-lipid nanoparticle platform for bioprotac mediated degradation of oncofusion proteins in ewing sarcoma
Active Definitive Contract Awarded Last action
- Contract number
- 75F40126C00066
- Awardee
-
The Trustees Of The University Of Pennsylvania UEI GM1XX56LEP58
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $2,682,546
Award facts
- Opportunity
-
- FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Special Notice · FDABAA2600123 · Posted Nov 21, 2025
- Contract value 39% obligated
-
- $2,682,546.00 Current, with exercised options
- $6,954,936.00 Potential, with all options
- Completion date 2% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 257 offers Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $2,682,546 |
About this award
The Food and Drug Administration awarded a firm fixed price definitive contract to The Trustees of The University of Pennsylvania for targeted polymer-lipid nanoparticle platform development for bioprotac-mediated degradation of oncofusion proteins in Ewing sarcoma, with a ceiling value of $6,954,936, on September 15, 2026.
Work is performed in Philadelphia, PA. The contract extends through September 23, 2031. The award originated from the FY26 FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science, a special notice posted November 21, 2025, seeking basic and applied research and development proposals to support regulatory science and innovation across FDA-regulated domains. The solicitation operated under FAR 6.102(d)(2) and 35.016 and classified work under NAICS 541714 (Research and Development in Biotechnology) and PSC AJ11 (General Science and Technology R&D Services). The opportunity was posted with a Stage One submittal due date of February 24, 2026, and carried no set-aside restriction. No subcontractors are named in the award documentation.
Quick answers
Who was awarded contract 75F40126C00066?
75F40126C00066 was awarded to The Trustees Of The University Of Pennsylvania by Food and Drug Administration (Department of Health and Human Services) on September 15, 2026.
How much is contract 75F40126C00066 worth?
The government has obligated $2,682,546 on 75F40126C00066. Its potential value, with all options, is $6,954,936.
Was contract 75F40126C00066 competed?
The extent of competition for 75F40126C00066 was full and open competition. The government received 257 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award